ReuseUnless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version -refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.
TakedownIf you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
1
TITLE
CONFLICTS OF INTEREST 36There are no conflicts of interest to declare relating to any of the named authors of this manuscript. Despite international guidelines, optimal delivery models of late effects (LE) services for HSCT 52 patients are unclear from clinical, organisational and economic viewpoints. To scope current LE 53 service delivery models within the UK-NHS, in 2014 we surveyed the 27 adult allogeneic HSCT 54 centres using a 30 question online tool, achieving a 100% response rate. 55Most LE services were led and delivered by senior physicians (>80% centres). Follow-up was usually 56 provided in a dedicated allograft or LE clinic for the first year (>90% centres), but thereafter attrition 57 meant only ~50% of patients were followed after 5 years. Most centres (69%) had an SOP for long-58 term monitoring but access to a LE Multi-Disciplinary Team was rare (19% centres). Access to 59 medical specialities necessary for LE management was good, but specialist interest in long-term 60 HSCT complications was uncommon. Some screening (endocrinopathy, cardiovascular) was near 61 universal, but other areas were more limited (mammography, cervical smears).